Clinical Trials Logo
  1. Home
  2. Safety and Tolerability
  3. NCT01952548
  4. Details
NCT01952548 Clinical Trial

Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers

Safety and Tolerability Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01952548
Other study ID # K-312-1.01US
Secondary ID
Status Completed
Phase Phase 1
First received September 19, 2013
Last updated December 30, 2013
Start date May 2013

Study information
Verified date December 2013
Source Kowa Research Institute, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study will test single doses of the study drug in increasing amounts to see if it is safe.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date
Est. primary completion date December 2013
Accepts healthy volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Subject provides written informed consent before any study-specific evaluation is performed.

- Subject is a healthy adult male or a female of non-childbearing potential between the ages of 18 and 45 years, inclusive.

- Subject has a body mass index of 18.5 to 32 kg/m2, inclusive.

Exclusion Criteria:

- Subject is a woman who is of childbearing potential or is breastfeeding.

- Subject has the presence of an active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

Intervention

Drug:
• K-312

• Placebo

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Kowa Research Institute, Inc.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Adverse Events 10 Days
See also
  Status Clinical Trial Phase
Recruiting NCT06000891 - A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Phase 1
Active, not recruiting NCT05997641 - Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects Phase 1
Completed NCT06181760 - A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers Phase 1
Recruiting NCT05907382 - Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects Phase 1
Recruiting NCT06453824 - SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants Phase 1
Completed NCT05431634 - Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants Phase 1
Recruiting NCT06331884 - Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab) Phase 1
Completed NCT03046589 - DP13 SAD & MAD in Healthy Male Subjects Phase 1
Recruiting NCT06079541 - Phase 1 Clinical Study of JMKX003142 Tablets Phase 1
Completed NCT05223660 - A Phase I Pharmacokinetics Study for KT07 Capsule Phase 1
Completed NCT01907867 - Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin Phase 1
Completed NCT03809052 - A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects Phase 1
Completed NCT03853421 - Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin Phase 1
Terminated NCT03307512 - PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD Phase 2
Completed NCT03685708 - HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) Phase 2
Completed NCT03702231 - Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) Phase 2
Completed NCT03817346 - Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers Phase 1
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1
Completed NCT05451667 - Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers Phase 1
Completed NCT02029482 - Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects Phase 1